EUVIMEDEUVIMED entdecken
Crossref

Unlocking Sulforaphane’s Potential in Friedreich Ataxia: Further Evidence from Preclinical Investigations Using Induced Pluripotent Stem Cell-Derived Sensory Neurons

Wenyao Yang, Bruce Thompson, Sara Miellet, Marnie Maddock, Marek Napierala, Mirella Dottori, Faith A A Kwa iD

Antioxidants & Redox Signaling · 2026

DOI: 10.1177/15230864261470377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antioxidants & Redox Signaling, 2026. Verfasst von Wenyao Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Sciences, Swinburne University of Technology, Hawthorn, Australia. Hauptthemen laut MEDLINE: Isothiocyanates, Friedreich Ataxia, Sulfoxides, Induced Pluripotent Stem Cells. Die Arbeit nennt 97 Literaturangaben. Gefördert von: Melbourne School of Health Sciences at the University of Melbourne, Medical Research Future Fund Stem Cell Therapies Mission, School of Health Sciences at Swinburne University of Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Friedreich ataxia (FRDA) is a neurodegenerative disorder typically caused by autosomal recessive inheritance of expanded guanine–adenine–adenine (GAA) repeats (>56) in both alleles of the frataxin ( FXN ) gene, leading to FXN protein deficiency. Omaveloxolone (Omav) is the only approved therapy. Therefore, further therapeutic options are essential. Previously, we showed that sulforaphane (SF) increases FXN expression and modulates epigenetic, inflammatory, and oxidative stress pathways in sensory neurons from a patient induced pluripotent stem cells (iPSCs) with 550 GAA1 repeats (FA2). Here, we compared SF, Omav, and dimethyl fumarate (DMF) treatment in sensory neurons derived from three patient iPSC lines with varying GAA1 repeats: FA1 (867), FA2, and FA3 (450).

Results

In FA1, SF treatment improved cell viability and reduced oxidative stress and inflammation. In FA3, SF increased cell viability, FXN protein levels, and gene and protein expression of redox markers, while targeting dysregulated epigenetic mechanisms and inflammation. All three lines showed SF’s consistent anti-oxidant and anti-inflammatory effects. Responses to Omav and DMF varied across the FA lines with less pronounced effects than when treated with SF. Overall, SF was more effective than Omav and DMF in improving cell viability and regulating FXN expression and epigenetic, redox, and inflammatory pathways. Innovation: These findings reveal variability in drug responses based on FRDA genetic profiles and position SF as a promising drug to address multiple pathological processes.

Conclusion

Our preclinical data support SF as a strong FRDA drug candidate. Clinical evaluation is warranted to confirm its full therapeutic potential. Antioxid. Redox Signal. 45, 561–580.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsothiocyanatesFriedreich AtaxiaSulfoxidesInduced Pluripotent Stem CellsSensory Receptor CellsHumansOxidative StressCell SurvivalFrataxinIron-Binding Proteins

Stichwörter der Autor:innen

Friedreich ataxiadimethyl fumarateepigeneticsfrataxininflammationomaveloxoloneoxidative stresssulforaphane

Substanzen

sulforaphaneIsothiocyanatesSulfoxidesFrataxinIron-Binding Proteins

Autor:innen und Institutionen

  • School of Health Sciences, Swinburne University of Technology, Hawthorn, Australia.
  • Melbourne School of Health Sciences, The University of Melbourne, Parkville, Australia.
  • School of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong, Australia.
  • Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, Texas, USA.

ORCID-Profile: Faith A A Kwa

Förderung

  • Melbourne School of Health Sciences at the University of Melbourne
  • Medical Research Future Fund Stem Cell Therapies Mission
  • School of Health Sciences at Swinburne University of Technology
  • Friedreich ataxia Research Alliance
  • University of Wollongong

Zitieren

APA

Yang, W., Thompson, B., Miellet, S., Maddock, M., Napierala, M., Dottori, M., & Kwa, F. A. A. (2026). Unlocking Sulforaphane’s Potential in Friedreich Ataxia: Further Evidence from Preclinical Investigations Using Induced Pluripotent Stem Cell-Derived Sensory Neurons. Antioxidants & Redox Signaling. https://doi.org/10.1177/15230864261470377

Vancouver

Yang W, Thompson B, Miellet S, Maddock M, Napierala M, Dottori M, et al. Unlocking Sulforaphane’s Potential in Friedreich Ataxia: Further Evidence from Preclinical Investigations Using Induced Pluripotent Stem Cell-Derived Sensory Neurons. Antioxidants & Redox Signaling. 2026. doi:10.1177/15230864261470377

BibTeX
@article{Yang2026,
  author = {Yang, Wenyao and Thompson, Bruce and Miellet, Sara and Maddock, Marnie and Napierala, Marek and Dottori, Mirella and Kwa, Faith A A},
  title = {Unlocking Sulforaphane’s Potential in Friedreich Ataxia: Further Evidence from Preclinical Investigations Using Induced Pluripotent Stem Cell-Derived Sensory Neurons},
  journal = {Antioxidants & Redox Signaling},
  year = {2026},
  doi = {10.1177/15230864261470377}
}
Kostenlos starten →